Previous 10 | Next 10 |
Checkpoint Therapeutics (NASDAQ: CKPT ): Q3 GAAP EPS of -$0.15 beats by $0.02 . More news on: Checkpoint Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage, immunotherapy and targeted oncology company, today announced financial results and recent corporate highlights for the third quarter ended September 30, 2...
Fortress Biotech ( FBIO ) has made significant progress since my 11/24/2018 article on the Fortress Biotech Inc. 9.375% Cum Conv Perp Red Pfd Registered Shs Series ( FBIOP ). Although FBIOP remains a speculative issue, it has appreciated in price from $17.58 to $20.00 since my last artic...
50% objective response rate observed in cutaneous squamous cell carcinoma (CSCC) 40% objective response rate observed in non-small cell lung cancer Well-tolerated safety profile across all cohorts Enrollment ongoing to support initial Biologics License Application submission in ...
NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor ...
The following slide deck was published by Checkpoint Therapeutics, Inc. in conjunction with this Read more ...
NEW YORK, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor ...
NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor...
Checkpoint Therapeutics (NASDAQ: CKPT ): Q2 GAAP EPS of -$0.15 beats by $0.01 . More news on: Checkpoint Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
NEW YORK, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor ...
News, Short Squeeze, Breakout and More Instantly...
Checkpoint Therapeutics Inc. Company Name:
CKPT Stock Symbol:
NASDAQ Market:
Checkpoint Therapeutics Inc. Website:
WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review Check...
Collaboration explores the potential synergistic effects of Checkpoint’s anti-PD-L1, cosibelimab, in combination with the autologous T cell therapy, Immuncell-LC YONGIN, South Korea and WALTHAM, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- GC Cell (KRX: 144510.KS) and Checkpoin...
WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has entered into a definitive agreement with a single healthcare-dedicated institutional in...